X4 Pharmaceuticals (XFOR) News Today $0.61 +0.00 (+0.44%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Unusually active option classes on open December 10thDecember 11, 2024 | markets.businessinsider.comTraders Buy High Volume of X4 Pharmaceuticals Call Options (NASDAQ:XFOR)December 11, 2024 | americanbankingnews.comX4 Pharmaceuticals to present on Phase 3 study of MavorixaforDecember 5, 2024 | markets.businessinsider.comX4 Pharmaceuticals to Present Trial-in-Progress Poster on Phase 3 Study of Mavorixafor in Chronic Neutropenia at 66th ASH Annual Meeting & ExpositionDecember 4, 2024 | markets.businessinsider.comX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 3, 2024 | globenewswire.comB. Riley Expects Stronger Earnings for X4 PharmaceuticalsX4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) - Equities research analysts at B. Riley raised their FY2024 earnings per share (EPS) estimates for X4 Pharmaceuticals in a research note issued to investors on Monday, November 18th. B. Riley analyst K. Patel now expects that the company willNovember 20, 2024 | marketbeat.comResearch Analysts Set Expectations for XFOR FY2024 EarningsX4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) - Equities research analysts at HC Wainwright decreased their FY2024 EPS estimates for shares of X4 Pharmaceuticals in a research note issued on Thursday, November 14th. HC Wainwright analyst S. Ramakanth now anticipates that the company will eNovember 18, 2024 | marketbeat.comX4 Pharmaceuticals price target lowered to $1.50 from $5 at H.C. WainwrightNovember 14, 2024 | markets.businessinsider.comXFOR: Positive Results for Phase 2 Trial of Mavorixafor in Chronic Neutropenia…November 14, 2024 | msn.comX4 Pharmaceuticals Inc (XFOR) Q3 2024 Earnings Call Highlights: Strategic Engagement and ...November 14, 2024 | finance.yahoo.comX4 Pharmaceuticals Reports Positive Trial Results and ProgressNovember 14, 2024 | markets.businessinsider.comX4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare ConferenceNovember 14, 2024 | globenewswire.comX4 Pharmaceuticals price target lowered to $4 from $5 at StifelNovember 14, 2024 | markets.businessinsider.comX4 Pharmaceuticals, Inc. (XFOR) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | seekingalpha.comX4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 13, 2024 | markets.businessinsider.comX4 Pharmaceuticals Posts Wider Loss In Q3 - Quick FactsNovember 13, 2024 | markets.businessinsider.comX4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 13, 2024 | globenewswire.comX4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)November 13, 2024 | globenewswire.comX4 Pharmaceuticals (XFOR) to Release Earnings on WednesdayX4 Pharmaceuticals (NASDAQ:XFOR) will be releasing earnings before the market opens on Wednesday, November 13, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=639867)November 6, 2024 | marketbeat.comX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 1, 2024 | globenewswire.comX4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024October 24, 2024 | globenewswire.comInsider Selling: X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) CEO Sells 31,897 Shares of StockOctober 17, 2024 | insidertrades.comPaula Ragan Sells 31,897 Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) StockX4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) CEO Paula Ragan sold 31,897 shares of the firm's stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $0.56, for a total value of $17,862.32. Following the completion of the sale, the chief executive officer now directly owns 1,025,816 shares in the company, valued at $574,456.96. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.October 16, 2024 | marketbeat.comActelis Networks Announces Follow-On Order from U.S. Department of Transportation Agency Expanding Footprint to New RegionsOctober 15, 2024 | globenewswire.comX4 Pharmaceuticals (NASDAQ:XFOR) Stock Quotes, Forecast and News SummaryOctober 9, 2024 | benzinga.comX4 Pharmaceuticals, Inc. (NASDAQ:XFOR) COO Sells $38,586.15 in StockOctober 9, 2024 | insidertrades.comActelis Receives Expansion Order for Major Italian National Transportation Infrastructure ProjectOctober 2, 2024 | globenewswire.comX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 1, 2024 | globenewswire.comActelis Networks Receives $200,000 Order to Provide Fast Upgrade and Modernization to US Army National Guard Base NetworkSeptember 26, 2024 | globenewswire.comGV 2016 GP, L.L.C.'s Net WorthSeptember 19, 2024 | benzinga.comX4 Pharmaceuticals, Inc. (NASDAQ:XFOR) is a favorite amongst institutional investors who own 51%September 18, 2024 | finance.yahoo.comActelis Receives New Significant Order for Major U.S. Department of Aerial Transportation AgencySeptember 9, 2024 | globenewswire.comX4 Pharmaceuticals (NASDAQ:XFOR) Shares Down 1.3% X4 Pharmaceuticals (NASDAQ:XFOR) Stock Price Down 1.3%September 6, 2024 | marketbeat.comX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 3, 2024 | globenewswire.comActelis Networks to Participate in H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | globenewswire.comX4 Pharmaceuticals to Participate in Upcoming September Investor ConferencesAugust 28, 2024 | globenewswire.comActelis Receives New Order for Intelligent Traffic System (ITS) Networking in New York City Metro AreaAugust 27, 2024 | globenewswire.comActelis Announces Strategic Partnership to Launch AI-Powered Cybersecurity SaaS for IoT NetworksAugust 19, 2024 | globenewswire.comActelis Networks Reports Q2 2024 Results: 372% Sequential Revenue Growth, 81% Year-Over-Year Increase, and Positive EBITDAAugust 14, 2024 | globenewswire.comXFOR: First Commercial Sales of XOLREMDI™…August 13, 2024 | msn.comHC Wainwright Comments on X4 Pharmaceuticals, Inc.'s FY2028 Earnings (NASDAQ:XFOR)X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) - Analysts at HC Wainwright increased their FY2028 EPS estimates for X4 Pharmaceuticals in a research note issued to investors on Friday, August 9th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of $0.3August 12, 2024 | marketbeat.comX4 Pharmaceuticals, Inc. (XFOR) Q2 2024 Earnings Call TranscriptAugust 10, 2024 | seekingalpha.comX4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate UpdatesAugust 8, 2024 | globenewswire.comX4 Pharmaceuticals Q2 2024 Earnings PreviewAugust 7, 2024 | msn.com48Q.SG,0P0001JBQG,0 (48Q.SG)August 7, 2024 | nz.finance.yahoo.comActelis Secures New Orders for Cyber-Hardened Network Solutions for Two Major German Utility ProvidersAugust 2, 2024 | globenewswire.comX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 1, 2024 | globenewswire.comX4 Pharmaceuticals (XFOR) to Release Quarterly Earnings on ThursdayX4 Pharmaceuticals (NASDAQ:XFOR) will be releasing earnings before the market opens on Thursday, August 8, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=614861)August 1, 2024 | marketbeat.comX4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Short Interest Up 18.9% in JulyX4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) was the target of a large increase in short interest in the month of July. As of July 15th, there was short interest totalling 16,510,000 shares, an increase of 18.9% from the June 30th total of 13,880,000 shares. Based on an average daily trading volume, of 2,980,000 shares, the short-interest ratio is presently 5.5 days.July 28, 2024 | marketbeat.comActelis Receives Over $150,000 in New Military Orders for New Cyber-Hardened Networking SolutionsJuly 22, 2024 | globenewswire.com Get X4 Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XFOR and its competitors with MarketBeat's FREE daily newsletter. Email Address URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)It’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life-changing for those who are prepared. Why? Because altcoin prices are about to explode. >> Register for the Workshop Now XFOR Media Mentions By Week XFOR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. XFOR News Sentiment▼0.800.60▲Average Medical News Sentiment XFOR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. XFOR Articles This Week▼03▲XFOR Articles Average Week Get X4 Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XFOR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies YMAB News Today SIGA News Today KRRO News Today AURA News Today KALV News Today IGMS News Today SANA News Today RGNX News Today TSHA News Today GHRS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:XFOR) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding X4 Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share X4 Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
